Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling

Experimental Hematology

Volumn 39, Issue 5, 2011, Pages 591-600

  Gueller, Saskia ^a   Hehn, Sina ^a   Nowak, Verena ^b   Gery, Sigal ^b   Serve, Hubert ^a   Brandts, Christian H ^a   Koeffler, H Phillip ^b,c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; FIP1L1 PDGFRA PROTEIN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN LNK; TEL PDGFRB PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN;

ANIMALS; CELLS, CULTURED; HUMANS; MICE; NIH 3T3 CELLS; PROTEIN BINDING; PROTEINS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79955152263     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.02.001     Document Type: Article

References (40)

1. Rudd C.E. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE 2001, 2001:E1.
2. Ema H., Sudo K., Seita J., et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell 2005, 8:907-914.
3. Nobuhisa I., Takizawa M., Takaki S., et al. Regulation of hematopoietic development in the aorta-gonad-mesonephros region mediated by Lnk adaptor protein. Mol Cell Biol 2003, 23:8486-8494.
4. Takaki S., Morita H., Tezuka Y., Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein. Lnk. J Exp Med 2002, 195:151-160.
5. Velazquez L., Cheng A.M., Fleming H.E., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002, 195:1599-1611.
6. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004, 200:569-580.
7. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105:4604-4612.
8. Buza-Vidas N., Antonchuk J., Qian H., et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 2006, 20:2018-2023.
9. Takizawa H., Kubo-Akashi C., Nobuhisa I., et al. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein. Lnk. Blood 2006, 107:2968-2975.
10. Maures T.J., Chen L., Carter-Su C. Nucleocytoplasmic shuttling of the adapter protein SH2B1beta (SH2-Bbeta) is required for nerve growth factor (NGF)-dependent neurite outgrowth and enhancement of expression of a subset of NGF-responsive genes. Mol Endocrinol 2009, 23:1077-1091.
11. Qian X., Ginty D.D. SH2-B and APS are multimeric adapters that augment TrkA signaling. Mol Cell Biol 2001, 21:1613-1620.
12. Wakioka T., Sasaki A., Mitsui K., et al. APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 1999, 13:760-767.
13. Wang J., Riedel H. Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter. J Biol Chem 1998, 273:3136-3139.
14. Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A., Ronnstrand L. The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit. Biochem J 2003, 370:1033-1038.
15. Yokouchi M., Wakioka T., Sakamoto H., et al. APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. Oncogene 1999, 18:759-767.
16. Li Y., He X., Schembri-King J., Jakes S., Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol 2000, 164:5199-5206.
17. Gueller S., Goodridge H.S., Niebuhr B., et al. Adaptor protein Lnk inhibits c-Fms mediated macrophage function. J Leukoc Biol 2010, 88:699-706.
18. Baxter R.M., Secrist J.P., Vaillancourt R.R., Kazlauskas A. Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J Biol Chem 1998, 273:17050-17055.
19. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
20. Doolittle R.F., Hunkapiller M.W., Hood L.E., et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 1983, 221:275-277.
21. Waterfield M.D., Scrace G.T., Whittle N., et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983, 304:35-39.
22. Irusta P.M., DiMaio D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J 1998, 17:6912-6923.
23. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
24. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
25. Stover E.H., Chen J., Folens C., et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A 2006, 103:8078-8083.
26. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
27. Gueller S., Gery S., Nowak V., et al. Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J 2008, 415:241-245.
28. Gery S., Gueller S., Chumakova K., et al. Adaptor protein Lnk, negatively regulates the mutant MPL, MPLW515L, associated with myeloproliferative disorders. Blood 2007, 110:3360-3364.
29. Claesson-Welsh L., Eriksson A., Moren A., et al. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. Mol Cell Biol 1988, 8:3476-3486.
30. Claesson-Welsh L., Eriksson A., Westermark B., Heldin C.H. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc Natl Acad Sci U S A 1989, 86:4917-4921.
31. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A 1996, 93:14845-14850.
32. Gleich G.J., Leiferman K.M. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol 2009, 145:271-285.
33. Vandenberghe P., Wlodarska I., Michaux L., et al. Clinical and molecular features of FIP1L1-PDFGRA () chronic eosinophilic leukemias. Leukemia 2004, 18:734-742.
34. Wilbanks A.M., Mahajan S., Frank D.A., et al. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol 2000, 28:584-593.
35. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
36. David M., Cross N.C., Burgstaller S., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64.
37. Simon C., Dondi E., Chaix A., et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 2008, 112:4039-4047.
38. Fitau J., Boulday G., Coulon F., Quillard T., Charreau B. The adaptor molecule Lnk negatively regulates tumor necrosis factor-alpha-dependent VCAM-1 expression in endothelial cells through inhibition of the ERK1 and -2 pathways. J Biol Chem 2006, 281:20148-20159.
39. Levkowitz G., Waterman H., Ettenberg S.A., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4:1029-1040.
40. Bersenev A., Wu C., Balcerek J., Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008, 118:2832-2844.